Active Ingredient: Ibrutinib   Dosage Forms & Strengths:   Capsules: 70 mg and 140 mg   Tablets: 140 mg, 280 mg, 420 mg, and 560 mg   Mechanism of Action: Bruton's tyrosine kinase Inhibitor (BTKi)  First Approval: US (13 Nov 2013), EU (Oct 2014)   Revenue Analysis Imbruvica is an oral therapy that inhibits a protein called Bruton's tyrosine kinase. Imbruvica was one…